Vaxcyte, Inc. (PCVX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en San Carlos, CA, United States. El CEO actual es Grant E. Pickering.
PCVX tiene fecha de IPO 2020-06-12, 414 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $9.03B.
Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing novel protein vaccines to prevent and treat bacterial infectious diseases. The company's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials for invasive pneumococcal disease and pneumonia. Vaxcyte's pipeline also includes VAX-XP to address emerging strains and antibiotic resistance, VAX-A1 targeting Group A Strep, and VAX-PG designed to treat periodontitis. Founded in 2013 and headquartered in San Carlos, California, the company was formerly known as SutroVax, Inc. before rebranding in May 2020.
